#TelomereBiology
LightNews LightNews
cgconsortium.bsky.social
We’re pleased to share Dr. Sharon Savage’s keynote at #CGCAnnual2025.
She discusses the link between telomere biology and cancer, including research on telomere length, cancer risk, and genetic factors.

Watch: buff.ly/5v34gSC

#TelomereBiology #CancerResearch #Genomics #CGCAnnual2025 #Keynote
February 18, 2026 at 6:04 PM
teamtelomere.bsky.social
#TTSummit2026 #TBDCommunity #TelomereBiology #RareDiseaseCommunity #AdvocacyAndResearch #MissoulaMontana #Missoula #TelomereBiologyDisorders #RareTogether #TelomereBiologyDisorders #TBDawarenessMonth #RareDisease #DyskeratosisCongenita #IPF #ILD #Liver #AplasticAnemia #AdvocacyInAction
January 31, 2026 at 5:06 PM
arxivlens.bsky.social
Dissecting the pleiotropic genetic architecture linking telomere biology to chronic respiratory diseases and lung function
Chang, S., Fan, Y. et al.
Paper
Details
#TelomereBiology #ChronicRespiratoryDiseases #LungFunctionGenetics
July 19, 2025 at 11:53 PM
teamtelomere.bsky.social
📢 Learn more about screening and transplants in our guidelines: bit.ly/TBD_Guidelines
#RareAware #TelomereBiology #RareLiverDisease #Advocacy #Education #TBD #BetterTogether
Diagnosis & Management Guidelines | Team Telomere
bit.ly
February 20, 2025 at 8:26 PM
teamtelomere.bsky.social
🚨 Big news for the TBD community! Elixirgen Therapeutics has received FDA RMAT designation for EXG-34217, a gene therapy for TBDs with bone marrow failure. This fast-tracks development, bringing us closer to potential treatment!
🔗 Learn more in our bio
#TelomereBiology
Image 1 (What Does This Mean?): A digital graphic with a dark blue background and white text. The heading reads “WHAT DOES THIS MEAN?” in red. The text explains that Elixirgen Therapeutics has received RMAT designation from the FDA for EXG-34217, a gene therapy for Telomere Biology Disorders (TBDs) with bone marrow failure. The designation allows for fast-tracked development and review, bringing it closer to potential treatment options. A small blue banner at the bottom directs viewers to read the full article at the link provided. Image 2 (Team Telomere News): A digital news-style graphic with a white background. The heading in red reads “TEAM TELOMERE NEWS.” The text states that Elixirgen Therapeutics has been granted FDA RMAT designation for EXG-34217 for the treatment of Telomere Biology Disorders. The date is February 13, 2025, and the source is Elixirgen Therapeutics, Inc. Logos for Elixirgen Therapeutics and Team Telomere appear in the lower half of the image. A blue banner at the bottom prompts viewers to read the full article via the link in the caption. Image 3 (How Can I Learn More?): A digital graphic with a white background and dark blue text. The heading in red reads “HOW CAN I LEARN MORE?” The text encourages viewers to read the news release for more information and mentions that EXG-34217 is currently in Phase I/II clinical trials and open for enrollment for patients aged 12 and older. A blue banner at the bottom directs viewers to read the full article at the link provided.
February 19, 2025 at 11:02 PM
teamtelomere.bsky.social
Today we celebrate the amazing women in the TBD and rare disease communities. A special shoutout to Elizabeth Blackburn and Carol Greider, whose discovery of telomerase changed how we understand aging, cancer, and telomere biology.

#WomenInScience #TeamTelomere #Trailblazers #TelomereBiology
Graphic celebrating the International Day of Women and Girls in Science, featuring seven women scientists in a collage on a blue background. The image includes icons representing science: a DNA strand, a beaker with a scientist silhouette, and molecular structures. These women symbolize the contributions of female scientists in advancing research and innovation. The Team Telomere logo appears in the top left corner.
February 11, 2025 at 9:23 PM
jmirpub.bsky.social
JMIR Formative Res: “Crying in the Wilderness”—The Use of Web-Based Support in Telomere Biology Disorders: Thematic Analysis #TelomereBiology #RareDiseases #GeneticDisorders #WebSupport #PatientCare
“Crying in the Wilderness”—The Use of Web-Based Support in Telomere Biology Disorders: Thematic Analysis
Background: Web-based information and social support are commonly used in rare disease communities where geographic dispersion and limited provider expertise complicate in-person support. We examined web-based resource use among caregivers of individuals…
dlvr.it
December 16, 2024 at 3:49 PM
mainzuniversity.bsky.social
Mainz molecular biologist Peter Baumann elected as new @EMBO member http://www.uni-mainz.de/presse/aktuell/9160_ENG_HTML.php
(photo/©: IMB Mainz) @imbmainz #MolecularBiology #ChromosomeBiology #Research #telomeres #telomerase #TelomereBiology
December 12, 2024 at 5:20 PM